Stopping Anticoagulation at Nursing Home Entry: No Stroke Signal, Higher Mortality
This target trial emulation gives anticoagulation stewardship pharmacists the first large, entry-anchored comparison of continuing versus stopping anticoagulation in long-term care residents with atrial fibrillation, while exposing how mortality confounds interpretation.
📅 Journal publication: Oct 1, 2026·Last updated: Nov 19, 2026
Does stopping anticoagulation increase mortality in atrial fibrillation?
Anticoagulation discontinuation in long-term care residents with atrial fibrillation has significant implications for stroke and bleeding management. Anticoagulation discontinuation did not increase stroke or bleeding risk but showed higher mortality (HR, 1.27; 95% CI, 1.23-1.31). Findings suggest stroke and bleeding risks remain stable after anticoagulation discontinuation; however, higher mortality requires consideration of individual patient factors. Anticoagulation discontinuation did not raise stroke or bleeding risks but increased mortality in long-term care residents with atrial fibrillation.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kapoor A, Chen Z, Patel J, Ye Z, Lin H, Barnes G, Crawford S, Gurwitz JH
Citation:Kapoor A, Chen Z, Patel J, et al. Stroke and Bleeding Risk in Long-Term Care Residents With Atrial Fibrillation Who Discontinue Anticoagulation. JAMA network open. 2026;9(10):e2640964. doi:10.1001/jamanetworkopen.2026.40964